The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey
Abstract
BACKGROUND: : The predominant symptoms of inflammatory bowel disease (IBD) are diarrhoea, abdominal pain, gastrointestinal bleeding, weight loss, malnutrition and fatigue. These symptoms can have substantial psychosocial implications and cause sufferers to limit their lifestyles, with consequent impact on quality of life (QoL). AIMS: : To survey the impact of IBD on peoples' lives as well as opinions of treatment and patient-doctor communication in a large European cohort of patients. SUBJECTS AND METHODS: : Seven organisations affiliated with the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) distributed questionnaires to 12,200 members between May and August 2005. In total, 5636 responses were received and analysed using descriptive statistics. RESULTS: : Of 5576 patients with evaluable responses, 1000 (17.9%) were not currently receiving any treatment, and 3109 (55.8%) were currently receiving anti-inflammatory/5-aminosalicylic acid, 1143 (25.9%) receiving immunomodulators, and 1076 (19.3%) receiving steroids (biologics constituted 4%; however, at the time of this survey they were not approved for use in treating patients with UC). Three quarters were either very (n=2233, 40.0%) or somewhat (n=2010, 36.0%) satisfied with the results obtained from their current treatment medication. If given a choice, 4819 (86.4%) said they would rather try a new type of drug therapy than undergo surgery. However, only 2182 (39.1%) reported that their doctor talked to them about newly developed treatments. Three quarters (75.6%, n=4213) reported that symptoms affect their ability to enjoy leisure activities, while over two thirds (68.9%, n=3841) felt symptoms affected their ability to perform at work. However, nearly half (n=2666, 47.8%) reported that their doctor does not ask about the impact of symptoms on their QoL. For those patients who received immunomodulators, 72.7% reported QoL improvements (1462/2012) while 72.8% reported QoL improvements with steroids (2622/3601). 75% of patients with CD who received biologic therapy (6% of responders) stated that their QoL improved following biologic therapy. CONCLUSIONS: IBD symptoms have a substantial impact on patients' lives, and QoL as well as new treatments should be an important feature of patient-physician discussions. The survey results may point to areas where support of IBD patients might be improved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Guidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Treatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities
Hanauer, S. B. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000195385.19268.68 · Cited by 968
Role of Cytokines in the Pathogenesis of Inflammatory Bowel Disease
Papadakis, K. A., & Targan, S. R. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.289 · Cited by 714
Clinical, biological, and endoscopic picture of attacks of Crohn's disease
Modigliani, R., Mary, J.-Y., Simon, J.-F., Cortot, A., Soule, J.-C., Gendre, J.-P., & Rene, E. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90002-i · Cited by 699
Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
Epidemiology of inflammatory bowel disease
Loftus, E. V., & Sandborn, W. J. (2002) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(01)00002-4 · Cited by 542
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
Bouhnik, Y., Scemama, G., Taï, R., Matuchansky, C., Rambaud, J.-C., Lémann, M., Modigliani, R., & Mary, J.-Y. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90402-x · Cited by 466
(2005) · PubMed · Cited by 298
EPIDEMIOLOGY AND THE NATURAL COURSE OF INFLAMMATORY BOWEL DISEASE
Andres, P. G., & Friedman, L. S. (1999) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70056-x · Cited by 288
Delaney, C. P., Fazio, V. W., Remzi, F. H., Hammel, J., Church, J. M., Hull, T. L., Senagore, A. J., Strong, S. A., & Lavery, I. C. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000080825.95166.26 · Cited by 273
Sewitch, M. J., Abrahamowicz, M., Bitton, A., Daly, D., Wild, G. E., Cohen, A., Katz, S., Szego, P. L., & Dobkin, P. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03800.x · Cited by 192
Why do patients with ulcerative colitis relapse?
Riley, S. A., Mani, V, Goodman, M. J., & Lucas, S. (1990) · Gut · doi:10.1136/gut.31.2.179 · Cited by 180
Female Infertility After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis
Johnson, P., Richard, C., Ravid, A., Spencer, L., Pinto, E., Hanna, M., Cohen, Z., & McLeod, R. (2004) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-0570-7 · Cited by 177
Concerns of patients with inflammatory bowel disease: results from a clinical population
Rooy, E. C. D., Toner, B. B., Maunder, R., Greenberg, G. R., Baron, D., Steinhart, A. H., McLeod, R. S., & Cohen, Z. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03877.x · Cited by 139
Outcome of a conservative approach in severe ulcerative colitis
Daperno, M., Sostegni, R., Scaglione, N., Ercole, E., RIGAZIO, C., Rocca, R., & Pera, A. (2003) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.04.001 · Cited by 91
Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs.
Williams, J. P., & Meyers, J. A. (2002) · PubMed · Cited by 84
Communicating with Patients With Inflammatory Bowel Disease
Husain, A., & Triadafilopoulos, G. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200407000-00020 · Cited by 76
Crohn's disease: step up or top down therapy
Hanauer, S. B. (2003) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2003.0361 · Cited by 71
Psychosocial aspects of inflammatory bowel disease
Casati, J., & Toner, B. B. (2000) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)80006-8 · Cited by 71
Hommes, D. W., Baert, F., Assche, G. V., Caenepeel, F., Vergauwe, P. L., Tuynman, H. A. R. E., Vos, M. D., van Deventer, S. J. H., Stitt, L., Rutgeerts, P., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.064 · Cited by 59
Immune-mediated inflammatory disorders
Edwards, C. J. (2002) · Medicine · doi:10.1383/medc.2002.30.8.1 · Cited by 21
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease
Zhang, S., Ermann, J., Succi, M. D., Zhou, A., Hamilton, M. J., Cao, B., Korzenik, J. R., Glickman, J. N., Vemula, P. K., Glimcher, L. H., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5657 · Cited by 467
European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Torres, J., Chaparro, M., Julsgaard, M., Katsanos, K., Zelinkova, Z., Agrawal, M., Ardizzone, S., Campmans-Kuijpers, M., Dragoni, G., Ferrante, M., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac115 · Cited by 281
Single-cell RNAseq reveals seven classes of colonic sensory neuron
Hockley, J. R. F., Taylor, T. S., Callejo, G., Wilbrey, A. L., Gutteridge, A., Bach, K., Winchester, W. J., Bulmer, D. C., McMurray, G., & Smith, E. S. J. (2019) · Gut · doi:10.1136/gutjnl-2017-315631 · Cited by 256
Rivière, P., Zallot, C., Desobry, P., Sabaté, J. M., Vergniol, J., Zerbib, F., Peyrin-Biroulet, L., Laharie, D., & Poullenot, F. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx100 · Cited by 111
Metadata
- Authors
- Ghosh, S., & Mitchell, R.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09
- Volume
- 1
- Issue
- 1
- Pages
- 10-20
- ISSN
- 1873-9946 (ISSN-L)
- OpenAlex
- W1988604248
- Cited by
- 335
- References
- 25
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.